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Variation in contrast-associated acute
kidney injury prophylaxis for percutaneous
coronary intervention: insights from the
Veterans Affairs Clinical Assessment,
Reporting, and Tracking (CART) program
Joseph Walker Keach1,2*, Maggie A. Stanislawski3,4, Anna E. Barón3,4, Mary E. Plomondon3,4, Paula Langner3,
Amit Amin5, Heather M. Gilmartin3,4, Stephen Waldo2,3 and Thomas M. Maddox5,6
Abstract
Background: Contrast-Associated Acute Kidney Injury (CA-AKI) is a serious complication associated with
percutaneous coronary intervention (PCI). Patients with chronic kidney disease (CKD) have an elevated risk for
developing this complication. Although CA-AKI prophylactic measures are available, the supporting literature is
variable and inconsistent for periprocedural hydration and N-acetylcysteine (NAC), but is stronger for contrast
minimization.
Methods: We assessed the prevalence and variability of CA-AKI prophylaxis among CKD patients undergoing PCI
between October 2007 and September 2015 in any cardiac catheterization laboratory in the VA Healthcare System.
Prophylaxis included periprocedural hydration with normal saline or sodium bicarbonate, NAC, and contrast
minimization (contrast volume to glomerular filtration rate ratio ≤ 3). Multivariable hierarchical logistic regression
models quantified site-specific prophylaxis variability. As secondary analyses, we also assessed CA-AKI prophylaxis
measures in all PCI patients regardless of kidney function, periprocedural hydration in patients with comorbid CHF,
and temporal trends in CA-AKI prophylaxis.
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Results: From 2007 to 2015, 15,729 patients with CKD underwent PCI. 6928 (44.0%) received periprocedural
hydration (practice-level median rate 45.3%, interquartile range (IQR) 35.5–56.7), 5107 (32.5%) received NAC
(practice-level median rate 28.3%, IQR 22.8–36.9), and 4656 (36.0%) received contrast minimization (practice-level
median rate 34.5, IQR 22.6–53.9). After adjustment for patient characteristics, there was significant site variability
with a median odds ratio (MOR) of 1.80 (CI 1.56–2.08) for periprocedural hydration, 1.95 (CI 1.66–2.29) for
periprocedural hydration or NAC, and 2.68 (CI 2.23–3.15) for contrast minimization. These trends were similar
among all patients (with and without CKD) undergoing PCI. Among patients with comorbid CHF (n = 5893), 2629
(44.6%) received periprocedural hydration, and overall had less variability in hydration (MOR of 1.56 (CI 1.38–1.76))
compared to patients without comorbid CHF (1.89 (CI 1.65–2.18)). Temporal trend analysis showed a significant and
clinically relevant decrease in NAC use (64.1% of cases in 2008 (N = 1059), 6.2% of cases in 2015 (N = 128, p = <
0.0001)) and no significant change in contrast-minimization (p = 0.3907).
Conclusions: Among patients with CKD undergoing PCI, there was low utilization and significant site-level
variability for periprocedural hydration and NAC independent of patient-specific risk. This low utilization and high
variability, however, was also present for contrast minimization, a well-established measure. These findings suggest
that a standardized approach to CA-AKI prophylaxis, along with continued development of the evidence base, is
needed.
Keywords: Prevention, AKI, CA-AKI, PCI, CKD
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Background
Contrast-Associated Acute Kidney Injury (CA-AKI), de-
fined as an absolute increase of serum creatinine ≥0.3
mg/dL or a relative increase ≥50% within 48–72 h of
contrast exposure, is a serious complication that may
occur after percutaneous coronary intervention (PCI)
[1]. CA-AKI is associated with increased morbidity, mor-
tality, hospital length of stay, and healthcare costs [2–5].
Chronic kidney disease (CKD) is the strongest independ-
ent risk factor for developing CA-AKI [6]. Unfortunately,
effective therapies to reduce the clinical impact of CA-
AKI among CKD patients are largely absent. Thus, the
primary therapeutic objective is to reduce the likelihood
of developing CA-AKI among these patients. Numerous
prophylactic interventions have been studied, including
periprocedural intravenous hydration with normal saline
(NS) or sodium bicarbonate, periprocedural administra-
tion of N-Acetylcysteine (NAC), and the minimization
of contrast volume [7–11]. The strength of evidence
supporting NAC and specific periprocedural hydration
protocols is weak, while minimizing procedural contrast
volume is much stronger [7–11]. Major society guide-
lines on CA-AKI prophylaxis in CKD patients are
currently lacking or contradictory [12, 13]. We hypothe-
sized that such variability in the literature and guidelines
would result in significant site-level practice variation in-
dependent of patient-specific factors. We also hypothe-
sized there would be less variability in well-established
interventions, such as contrast minimization. With this
in mind, we sought to assess the prevalence and vari-
ation of CA-AKI prophylactic measures utilized in CKD
patients undergoing PCI throughout the largest inte-
grated healthcare system in the United States, the Vet-
erans Affairs (VA) Healthcare System, with hopes of
identifying opportunities to improve the use of prophy-
lactic measures and reduce the incidence of CA-AKI.
Methods
The VA CART program is a national clinical quality ini-
tiative for all VA cardiac catheterization laboratories.
The program seeks to enhance the quality and safety of
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invasive cardiovascular procedures throughout the VA
[14]. The CART program collects standardized data on
all coronary angiograms and percutaneous coronary
interventions. Software is embedded in the VA elec-
tronic health record (EHR) and allows providers to enter
patient and procedural information as part of routine
clinical workflow. The CART software was designed
using standardized definitions which conform to the
definitions and standards of the American College of
Cardiology’s National Cardiovascular Data Registry
(ACC-NCDR) [15]. Quality checks of the data are peri-
odically conducted for completeness and accuracy [16].
CART data are combined with other VA data sources to
create a longitudinal data repository that supports qual-
ity assessment and improvement across the integrated
healthcare system.
We evaluated the use of periprocedural hydration with
normal saline or sodium bicarbonate, periprocedural
NAC, and the volume of contrast used during PCI rela-
tive to the patient’s GFR among patients with CKD
undergoing PCI between October 1st 2007 and Septem-
ber 30th 2015 at any VA cardiac catheterization labora-
tory. Prior studies have indicated that ratios of contrast
volume relative to GFR < 3 are associated with lower
CA-AKI risk [10]. CKD was defined as a glomerular fil-
tration rate (GFR) of 15-59 mL/min. The use of peripro-
cedural hydration was determined from in-lab records
and/or inpatient medications within 48 h of the proced-
ure and included the administration of normal saline
(NS) or intravenous sodium bicarbonate. Doses of peri-
procedural hydration < 100 mL were excluded to avoid
mistaking saline flushes and other small saline applica-
tions for CA-AKI pre-hydration. The median volume of
preprocedural hydration administered using this ap-
proach was 1000 ml (IQR: 500–1000ml). The use of
NAC was determined from in-lab records and/or out-
patient prescription data, including prescriptions for < 3
days of NAC given within 30 days of the procedure. The
PCI providers recorded contrast volume administration
in the EHR. GFR levels were calculated using the Modi-
fication of Diet in Renal Disease (MDRD) equation,
using the most recent serum creatinine value recorded
within 30 days of the PCI [17]. Patients were excluded
for currently receiving hemodialysis, missing pre-
procedural GFR assessment, missing longitudinal follow-
up data, undergoing repeat PCI, or receiving PCI at a
facility that performed < 50 PCIs over the time frame of
the study.
We assessed patient demographic and clinical risk fac-
tors, including age, race (white, black, other), sex, pres-
ence of congestive heart failure (CHF), GFR, and history
of diabetes, from the EHR using standard definitions
[15]. Lesion risk (defined as high or non-high) and num-
ber of stents were determined by data entered into the
CART application by physicians. Annual PCI volume
was assessed using CART data.
We compared demographic, clinical, and CA-AKI
prophylaxis characteristics of CKD patients undergoing
PCI by catheterization laboratory rates of periprocedural
hydration or NAC use, stratified into quartiles. We used
chi-squared tests for categorical variables and Mann–
Whitney Wilcoxon tests for continuous variables. We
then calculated unadjusted rates of 1) Periprocedural hy-
dration, 2) NAC use, 3) periprocedural hydration or
NAC use, and 4) contrast: GFR ≤ 3. Median site-level
rates with interquartile ranges were calculated.
Next, to evaluate the variation in use of site-level
CA-AKI prophylaxis measures independent of patient
CA-AKI risk, we calculated adjusted rates of 1) peri-
procedural hydration, 2) periprocedural hydration or
NAC, and 3) contrast: GFR ≤ 3. We did not model the
outcome of NAC due to instability in statistical models
caused by the wide variation in NAC use across sites
with very small numbers at many sites. For the analysis
of each prophylaxis measure, catheterization laborator-
ies were excluded if the prophylactic measure was used
infrequently (< 20 times over the study period) to avoid
unstable estimates. For the contrast: GFR ratio ana-
lyses, PCI patients who had missing contrast volume
information were excluded.
We used hierarchical regression models with VA
catheterization laboratory sites as a random intercept to
adjust for differences in lab case mix and to account for
the clustering of patients by lab, similar to the method-
ology used in calculating hospital-level readmission data
by the Centers for Medicare and Medicaid [18]. Based
on prior literature and a priori clinical knowledge, we
adjusted for the following patient level characteristics as-
sociated with CA-AKI: age, race, sex, CHF, GFR, dia-
betes, lesion risk (at least 1 high risk vs all non-high
risk), number of stents, and year of PCI, as well as site-
level annual PCI volume. Lesion risk and number of
stents were included as surrogates for PCI complexity.
For binary outcomes, we used logistic regression models
to calculate the predicted and expected probability of
each prevention measure at each lab and then multiplied
this ratio by the mean rate across sites to get the stan-
dardized site-level rate [19]. We estimated the 95%
confidence interval using bootstrap sampling. We con-
sidered the lab proportion as significantly different from
average when the 95% confidence interval did not in-
clude the system-wide mean.
We used the median odds ratio (MOR) to describe the
level of variation between sites, independent of patient
factors. The MOR can be interpreted as the odds that 2
patients with identical patient-level covariates from 2
randomly chosen sites will receive similar treatments, or
in our case, prophylaxis. An MOR of 1.0 indicates that
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no variation exists between sites, and identical patients
would receive identical treatment at different sites. The
MOR is always ≥1. For example, an MOR of 1.5
indicates a 50% likelihood that a similar patient would
receive different prophylactic measures at 2 different
sites. It provides an estimate of the effect of the
catheterization laboratory on the outcome, much as the
odds ratio (OR) estimates the effect of patient factors on
the outcome. Based on previous literature, an MOR >
1.2 indicates moderate site-level variation [20].
We also performed several secondary analyses. First, we
expanded the cohort to all patients undergoing PCI, regard-
less of kidney function. Methods for this analysis of all pa-
tients were identical to those used for the primary analysis.
Second, to evaluate the potential effect of comorbid
CHF on the volume of IV fluid administered for prophy-
laxis, we stratified the cohort by presence of CHF. We
then performed hierarchical regression models of peri-
procedural hydration, identical to those used for the pri-
mary analysis, to estimate use, and variation in use,
within each stratum.
Finally, to explore the temporal changes in prophy-
laxis, a linear trend test was applied to unadjusted rates
of use of each measure by fiscal year.
All statistical analyses were performed by the CART
Program Analytic Center using SAS version 9.4 (SAS In-
stitute Inc., Cary, North Carolina) and R 3.4.1 (R Core
Team (2019). The Colorado Multiple Institutional Re-
view Board approved the study.
Results
Between 2007 and 2015, 87,056 PCIs were performed
across the VA integrated healthcare system. As shown in
Fig. 1, PCIs were excluded if patients were currently re-
ceiving hemodialysis (N = 2727), missing pre-procedural
GFR assessment (N = 4567), without longitudinal follow-
up data (N = 2), undergoing repeat PCI (N = 15,588), sites
with < 50 PCIs over the time frame of the study (N = 37),
and or had normal kidney function (N = 48,406). Thus,
the cohort for our primary analysis included 15,729 pa-
tients with CKD undergoing PCI at 64 unique sites.
Fig. 1 Primary cohort flow diagram
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Table 1 shows the characteristics of the primary CKD
cohort, both overall and arranged by quartile of increas-
ing unadjusted rates of periprocedural hydration or
NAC use. Among these 15,729 patients, 6928 (44.0%) re-
ceived periprocedural hydration (practice-level median
rate 45.3%, interquartile range (IQR) 35.5–56.7), 5107
(32.5%) received NAC (practice-level median rate 28.3%,
IQR 22.8–36.9), and 9436 (60.0%) received periproce-
dural hydration or NAC (practice-level median rate 62.8,
IQR 50.7–72.4). The median contrast: GFR ratio was 3.6,
(IQR 2.5–5.1) and 4656 (36.0%) patients received con-
trast minimization (contrast: GFR ratio ≤ 3, practice-level
median rate 34.5, IQR 22.6–53.9). After adjusting for
patient-specific risk factors, the MOR for only periproce-
dural hydration was 1.80 (CI 1.59–2.08), for periproce-
dural hydration or NAC was 1.95 (confidence interval
[CI] 1.66–2.29), and contrast: GFR ratio ≤ 3 was 2.68 (CI
2.23–3.15) (Table 2; Figs. 2 and 3). The intracluster cor-
relation coefficient for periprocedural hydration was
0.07, for hydration or NAC, 0.13, and for contrast
minimization, 0.18.
For our secondary analysis of all PCI patients, we
included all patients undergoing PCI during the study
period regardless of kidney function. Among this co-
hort of 64,135 PCI patients, 22,888 (35.7%) received
periprocedural hydration, 8919 (13.9%) received NAC,
and 27,595 (43%) received periprocedural hydration or
NAC. The median contrast volume to GFR ratio was
2.5 (IQR 1.6–3.7) and 32,503 (62.3%) patients had a
contrast: GFR ratio < = 3. After adjustment, the MOR
for periprocedural hydration was 1.96 (CI 1.71–2.24),
and for periprocedural hydration or NAC use was
2.15 (CI 1.82–2.53). The MOR for a contrast: GFR ra-
tio ≤ 3 was 2.75 (CI 2.26–3.28) (Table 2; Supplemental
Figs. 1 and 2).
For our secondary analysis of comorbid CHF and peri-
procedural hydration, 5893 (37.5%) patients from our
primary cohort had CHF (9836 had CKD but not CHF).
2629 (44.61%) patients with CHF received periproce-
dural hydration, while 4299 (43.71%) of those without
CHF received hydration. After adjusting for patient-
specific risk factors, the MOR for any periprocedural hy-
dration among patients with CHF was 1.56 (1.38–1.76).
For those without CHF, the MOR was 1.89 (1.65–2.18)
(Supplemental Fig. 3).
Finally, for our secondary analysis of temporal
prophylaxis trends, there was a significant and clinic-
ally relevant decrease in NAC use over the study
period, with NAC being used in 64.1% of cases in
2008 (N = 12,059), and only 6.2% of cases in 2015
(N = 128, p = < 0.0001) (Supplemental Tables 1a, b, c).
Contrast minimization appeared to stay constant with
no significant trend change over the study period
(p = 0.3907).
Discussion
Our analysis of CA-AKI prophylaxis among patients
with CKD undergoing PCI in the national VA healthcare
system demonstrated low utilization of commonly
employed prophylactic measures, as well as a high level
of variability in practice patterns, independent of
patient-specific risk. This low utilization and high vari-
ability were present for well-established, as well as less
established, prophylactic measures and similar trends
were noted in PCI patients with and without CKD. We
expected there would be less variability in CA-AKI
prophylaxis in the highest risk population, patients with
CKD, compared to the general PCI population. We
found, however, that high levels of variability persisted
among CKD patients, with contrast minimization even
more variable in this population.
Among patients with CKD, periprocedural hydration
and NAC, both poorly-established interventions, were
administered in a little over half of procedures, and had
an MOR of 1.80, indicating that identical patients would
have roughly 2-fold greater odds of receiving hydration
or NAC by being treated in one facility compared to an-
other. However, the well-established measure of contrast
minimization had even higher variability by site (MOR
2.68). This demonstrates that identical patients with
CKD have almost 3-fold greater odds of receiving high
volumes of contrast in 1 cardiac catheterization labora-
tory compared to another.
Among patients with comorbid CHF, we found that
patients with CKD and comorbid CHF received peripro-
cedural hydration at a similar frequency (44.61% vs
43.71%). Furthermore, after risk adjustment, there was
less variability in periprocedural hydration of patients
with CHF than those without (MOR 1.56 vs 1.89, re-
spectively). This is likely related to provider preference
and avoidance of potential volume overload in patients
at high risk for this complication (patients with impaired
cardiac and renal function).
Our study evaluated 8 years of CA-AKI prophylaxis
practice patterns. During this time significant research
was published and subsequent guidelines updated. We
observed a statistically significant and clinically relevant
decrease in the use of NAC prophylaxis over the time
course of our study, falling from 64.1% of cases in 2008
to only 6.2% in 2015. This is likely related to high-
quality research demonstrating the lack of benefit of
NAC for CA-AKI prophylaxis, and the updated 2011
ACC/AHA/SCAI guidelines recommended against the
use of NAC [12]. Of note, the well-established prophy-
lactic measure of contrast-minimization remained rela-
tively low and constant throughout our study period.
Contrast-minimization was on average utilized only
36.0% of the time and ranged from 33.6 to 38.9% with
no significant increase in utilization over time.
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Table 1 Demographic and clinical characteristics of patients with CKD receiving PCI arranged by site quartile of unadjusted rates of
periprocedural hydration or NAC use
Variable Total
(N = 15,729)
QUARTILE 1
(N = 3507)
QUARTILE 2
(N = 4108)
QUARTILE 3
(N = 4511)
QUARTILE 4
(N = 3603)
p-value
Demographics
Age (Median (IQR)) 68.6 (63.6–76.9) 68.8 (63.5–76.8) 67.7 (63.1–75.6) 68.6 (63.4–76.9) 70.0 (64.3–78.7) <.0001
Male 15,429 (98.1%) 3439 (98.1%) 4022 (97.9%) 4438 (98.4%) 3530 (98.0%) 0.38
Race
White 13,613 (86.5%) 2997 (85.5%) 3525 (85.8%) 3919 (86.9%) 3172 (88.0%) <.0001
Black 1799 (11.4%) 421 (12.0%) 525 (12.8%) 515 (11.4%) 338 (9.4%)
Other 317 (2.0%) 89 (2.5%) 58 (1.4%) 77 (1.7%) 93 (2.6%)
Cormorbidities
Hypertension 14,973 (95.2%) 3332 (95.0%) 3953 (96.2%) 4242 (94.0%) 3446 (95.6%) <.0001
Hyperlipidemia 14,413 (91.6%) 3146 (89.7%) 3855 (93.8%) 4077 (90.4%) 3335 (92.6%) <.0001
Diabetes 9127 (58.0%) 2060 (58.7%) 2407 (58.6%) 2552 (56.6%) 2108 (58.5%) 0.14
Tobacco Use 9124 (58.0%) 1916 (54.6%) 2599 (63.3%) 2339 (51.9%) 2270 (63.0%) <.0001
Prior MI 6728 (42.8%) 1503 (42.9%) 1804 (43.9%) 1860 (41.2%) 1561 (43.3%) 0.071
Prior PCI 6018 (38.3%) 1328 (37.9%) 1602 (39.0%) 1743 (38.6%) 1345 (37.3%) 0.43
Congestive Heart Failure 5893 (37.5%) 1330 (37.9%) 1503 (36.6%) 1711 (37.9%) 1349 (37.4%) 0.56
Cerebrovascular Disease 3803 (24.2%) 881 (25.1%) 982 (23.9%) 1034 (22.9%) 906 (25.1%) 0.055
Peripheral Arterial Disease 4451 (28.3%) 970 (27.7%) 1152 (28.0%) 1220 (27.0%) 1109 (30.8%) 0.0016
Hx of CKD Dx 8707 (55.4%) 1876 (53.5%) 2319 (56.5%) 2308 (51.2%) 2204 (61.2%) <.0001
Chronic Obstructive Pulmonary
Disease
4136 (26.3%) 930 (26.5%) 1035 (25.2%) 1229 (27.2%) 942 (26.1%) 0.19
BMI (Median (IQR)) 29.9 (26.4–34.0) 30.0 (26.6–34.1) 30.1 (26.6–34.2) 29.7 (26.1–33.7) 29.9 (26.4–34.1) 0.0048
Chronic Depression 4407 (28.0%) 1004 (28.6%) 1263 (30.7%) 1213 (26.9%) 927 (25.7%) <.0001
Sleep Apnea 3596 (22.9%) 765 (21.8%) 1008 (24.5%) 993 (22.0%) 830 (23.0%) 0.014
Baseline Cholesterol (Median (IQR)) 157.7 (135.3–
185.0)
161.5 (138.0–
189.0)
160.1 (137.2–
188.0)
155.2 (133.0–
183.0)
154.0 (133.0–
181.0)
<.0001
Baseline LDL (Median (IQR)) 85.8 (67.7–108.4) 86.3 (68.3–110.0) 87.1 (68.0–109.2) 86.0 (68.0–108.3) 83.3 (66.0–106.0) <.0001
Baseline HDL (Median (IQR)) 36.7 (31.0–43.5) 36.6 (31.0–43.6) 36.5 (31.0–43.0) 36.3 (31.0–43.0) 37.1 (31.7–44.3) 0.0006
CKD class
3a 11,029 (70.1%) 2404 (68.5%) 2958 (72.0%) 3140 (69.6%) 2527 (70.1%) 0.02
3b 3927 (25.0%) 915 (26.1%) 981 (23.9%) 1135 (25.2%) 896 (24.9%)
4 773 (4.9%) 188 (5.4%) 169 (4.1%) 236 (5.2%) 180 (5.0%)
Baseline GFR (Median (IQR)) 50.4 (43.0–55.7) 50.0 (42.4–55.1) 50.9 (43.8–56.0) 50.6 (43.0–56.0) 50.2 (42.9–55.3) 0.0012
Procedural Details
PCI Status
Elective 9617 (61.1%) 2275 (64.9%) 2744 (66.8%) 2545 (56.4%) 2053 (57.0%) <.0001
Emergent/Urgent 6034 (38.4%) 1220 (34.8%) 1329 (32.4%) 1947 (43.2%) 1538 (42.7%)
Missing 78 (0.50%) 12 (0.3%) 35 (0.9%) 19 (0.4%) 12 (0.3%)
PCI Indication
STEMI 1094 (7.0%) 263 (7.5%) 252 (6.1%) 336 (7.4%) 243 (6.7%) <.00
NSTEMI 3515 (22.3%) 756 (21.6%) 789 (19.2%) 1074 (23.8%) 896 (24.9%)
Unstable Angina 3516 (22.4%) 682 (19.4%) 1154 (28.1%) 918 (20.4%) 762 (21.1%)
ACS 182 (1.2%) 39 (1.1%) 44 (1.1%) 74 (1.6%) 25 (0.7%)
Stable Angina 4693 (29.8%) 1218 (34.7%) 1119 (27.2%) 1285 (28.5%) 1071 (29.7%)
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To our knowledge, only a small number of studies
have investigated the prevalence of CA-AKI prophylactic
measure utilization, none of which analyzed contrast
minimization strategies, or PCI and CKD specifically
[21–24]. A 2008 single-center study by Weisbord et al.
prospectively identified 660 patients with CKD undergo-
ing intravenous and intra-arterial contrasted studies and
showed that periprocedural fluids were administered in
40% of patients and NAC was administered in 39.2%
[23]. A 2014 study by Lee et al. retrospectively analyzed
the incidence of CA-AKI and prevalence of prophylactic
measure utilization with intravenous contrasted com-
puted tomography (CT) scans. They identified 101,487
patients with 140,838 contrasted CT scans and found
the incidence of prophylactic medication utilization to
be 28.6%, mostly driven by NS use (26%) [24].
Compared to these, our study specifically analyzed the
prevalence of CA-AKI prophylaxis surrounding PCI in
patients with and without CKD, including contrast
minimization. Our finding of periprocedural hydration
or NAC administration in 43% of cases (patients with
and without CKD) is within range of prior literature. In
addition, we add to this literature with our demonstra-
tion of a high level of patient-adjusted variability in CA-
AKI prophylaxis among high-risk patients, including
contrast minimization, and accounting for patient-level
risk factors.
The significant variation in CA-AKI prophylaxis
likely reflects the ambiguity of the underlying data,
particularly in light of recent randomized clinical tri-
als. A study by Nijssen et al. demonstrated no benefit
when comparing periprocedural hydration with NS to
no intravenous hydration at all [25]. The PRESERVE
trial randomly assigned 5177 patients to receive peri-
procedural hydration with intravenous sodium bicar-
bonate or NS, as well as either NAC or placebo, in a
2-by-2 factorial design. The study demonstrated no
benefit of sodium bicarbonate compared to NS, as
well as no benefit of NAC when compared to placebo
[26].
Conflicting major society guidelines likely com-
pound the effect of the contradictory literature. The
2011 ACCF/AHA/SCAI guidelines for PCI recom-
mend periprocedural intravenous hydration without a
Table 1 Demographic and clinical characteristics of patients with CKD receiving PCI arranged by site quartile of unadjusted rates of
periprocedural hydration or NAC use (Continued)
Variable Total
(N = 15,729)
QUARTILE 1
(N = 3507)
QUARTILE 2
(N = 4108)
QUARTILE 3
(N = 4511)
QUARTILE 4
(N = 3603)
p-value
Other/Missing 2729 (17.4%) 549 (15.7%) 750 (18.3%) 824 (18.3%) 606 (16.8%)
At least 1 lesion of high risk 6586 (41.9%) 1578 (45.0%) 1535 (37.4%) 2056 (45.6%) 1417 (39.3%) <.0001
Number of stents (Median (IQR)) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.64
CA-AKI Prevention Measures
Mutually Exclusive Categories of Preventions
None 6293 (40.0%) 2028 (57.8%) 1778 (43.3%) 1537 (34.1%) 950 (26.4%) <.0001
Only NS 4329 (27.5%) 533 (15.2%) 1004 (24.4%) 1464 (32.5%) 1328 (36.9%)
Only NAC 2508 (15.9%) 691 (19.7%) 604 (14.7%) 572 (12.7%) 641 (17.8%)
NAC and Saline 2599 (16.5%) 255 (7.3%) 722 (17.6%) 938 (20.8%) 684 (19.0%)
Any NAC 5107 (32.5%) 946 (27.0%) 1326 (32.3%) 1510 (33.5%) 1325 (36.8%) <.0001
Any Hydration 6928 (44.0%) 788 (22.5%) 1726 (42.0%) 2402 (53.2%) 2012 (55.8%) <.0001
Hydration or NAC 9436 (60.0%) 1479 (42.2%) 2330 (56.7%) 2974 (65.9%) 2653 (73.6%) <.0001
Contrast use (N = 12,938) (N = 2988) (N = 3096) (N = 3720) (N = 3134)
Contrast (Median (IQR)) 175.0 (120.0–
246.0)
165.0 (100.0–
230.0)
175.0 (120.0–
240.0)
190.0 (132.0–
260.0)
165.0 (105.0–
235.0)
<.0001
Contrast:GFR (Median (IQR)) 3.6 (2.5–5.1) 3.4 (2.2–5.0) 3.6 (2.5–5.1) 4.0 (2.8–5.4) 3.5 (2.3–4.9) <.0001
Contrast:GFR≤ 3 4656 (36.0%) 1206 (40.4%) 1136 (36.7%) 1081 (29.1%) 1233 (39.3%) <.0001
Table 2 Risk-Adjusted Median Odds Ratio for CA-AKI
prophylaxis measures in PCI patients with CKD and all PCI
patients (CKD or normal kidney function)
CKD Patients All Patients
MOR 95% CI MOR 95% CI
Hydration 1.80 1.59–2.08 1.96 1.71–2.24
Hydration or NAC 1.95 1.66–2.29 2.15 1.82–2.53
Contrast:GFR Ratio≤ 3 2.68 2.23–3.15 2.75 2.26–3.28
Estimates risk-adjusted for the following: CHF, age, sex, race (white, black,
other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), # of stents,
year of PCI, and annual hospital PCI volume
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specific protocol for volume or timing of hydration
and recommend against NAC [12]. The 2012 KDIGO
guidelines recommend periprocedural intravenous hy-
dration without specific protocols for volume or tim-
ing of hydration, however they do recommend the
use of NAC [13]. Accordingly, this inconsistency in
the hydration and NAC guidelines makes our findings
of high variability in their utilization somewhat
expected.
In contrast to these inconsistencies, there is broad
consensus and guideline support for minimizing contrast
during PCI, and numerous studies have demonstrated a
contrast: GFR volume < 3 is associated with lower rates
of CA-AKI [10]. This makes our findings of high vari-
ability in contrast minimization, both in our overall
population and among those with CKD, very surprising.
Our study had several limitations, the first being that
our outcomes were determined from analyzing the
electronic health record, and some data may have been
incompletely or inaccurately recorded, with accuracy
varying by site. This could have resulted in inaccurate
measurement of prophylactic measures. Second, the re-
sults may be subject to confounding variables not
accounted for by our statistical models. We adjusted for
numerous variables associated with CA-AKI, however,
there could be unaccounted for confounders that influ-
enced our results. Third, we used an arbitrary volume of
> 100 mL periprocedural hydration as a cutoff for receiv-
ing prophylactic hydration. However, the most com-
monly used NS hydration protocols (3–4 mL/kg per
hour 4 h before and 4 h after contrast administration, or
1 mL/kg per hour 12 h before and 12 h after) would ad-
minister 1.5–2.0 l of NS for a typical 70 kg patient; thus
a cutoff of 100 mL of NS likely over estimates the rate of
prophylactic NS administration [25]. Fourth, there are
numerous other CA-AKI prophylactic strategies
Fig. 2 Plot of risk-adjusted, site-level rates of hydration and NAC prophylaxis in PCI patients with CKD. The estimates are shown with 95%
confidence intervals (CIs) for those that differ significantly from the system-wide average. Estimates are risk-adjusted for the following: CHF, age,
sex, race (white, black, other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), number of stents, year of PCI, and annual hospital
PCI volume
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available, including statin therapy and ascorbic acid,
which were not evaluated in this study. However, as
periprocedural hydration, NAC, and contrast
minimization have the strongest body of evidence sup-
porting their use, we believe they are adequate surro-
gates. Fifth, there is ongoing debate in the literature on
the prevalence and nature of CA-AKI, with some evi-
dence suggesting the prevalence is lower than originally
thought [27]. This underlying confusion, however, likely
leads to some of the variation we identified, and until
this condition is better understood practice variation will
continue. Sixth, we did not capture whether certain
nephrotoxic home medications were held or continued
(diuretics, NSAIDs, ACE/ARB/RAAS inhibitors, etc.).
This could have potentially informed our investigation
further on CA-AKI prophylactic provider behaviors. Sev-
enth, we did not adjust for elective vs. urgent/emergent
procedure type, nor the presence or absence of cardio-
genic shock. We did, however, adjust for the presence or
absence of CHF as well as lesion risk and number of
stents, which we felt were adequate surrogates. Eighth,
we acknowledge that contrast minimization may not
have been possible in certain cases and variability in this
may not necessarily reflect provider non-use of the
intervention.
Conclusion
In conclusion, our study demonstrated a low overall
prevalence of CA-AKI prophylaxis, and a high level of
site variation in VA catheterization laboratories for both
patients with CKD and the overall PCI population. This
variability was present with both established methods,
such as contrast minimization, and contestable methods,
such as hydration or NAC administration. There are
likely multiple factors causing this variability, including
conflicting literature, vague and contradictory guidelines,
and provider preference. Proven methods to prevent
CA-AKI, such as contrast minimization, should be stan-
dardized across the healthcare system, while further re-
search should be pursued to establish other effective
measures to prevent CA-AKI, and prospectively evaluate
the influence of standardized CA-AKI prophylaxis proto-
cols on patient outcomes.
Fig. 3 Plot of risk-adjusted site-level PCIs with contrast to GFR ratios ≤3 among PCI patients with CKD. The estimates are shown with 95%
confidence intervals (CIs) for those that differ significantly from the system-wide average. Estimates are risk-adjusted for the following: CHF, age,
sex, race (white, black, other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), number of stents, year of PCI, and annual hospital
PCI volume
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